Immune checkpoint inhibitors related connective tissue diseases
Abstract
Immune checkpoint inhibitors are drugs that used in cancer treatment and increased in the use day by day. Immune-related adverse events of almost any organs are reported with these drugs. Hepatitis, colitis, pneumonitis, rash, thyroiditis, hypophysitis are the most common. Immune-related adverse events are generally mild to moderate, with a frequency greater than 90%. Although the rheumatologic adverse events are reported less than others, the true incidence of these adverse events is not fully known. Arthralgia and arthritis are the most commonly reported rheumatic immune-related adverse events in immune checkpoint inhibitors. In addition, there are case reports related to myositis, sikka syndrome, scleroderma and sarcoidosis. Increased awareness of rheumatic adverse events is important for early diagnosis and treatment of these cases.
Keywords
References
- Calabrese L, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 2018;14(10):569-79.
- Pisetsky DS. Effects of immune checkpoint inhibitors on B cell: relationship to immune-related adverse events. Ann Rheum Dis 2018;77(6):795-6.
- Cappelli LC, Shah AA, Bingham CO 3rd. Immune-related adverse effects of cancer immunotherapy-implications for rheumatology. Rheum Dis Clin North Am 2017;43(1):65-78.
- Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occuring after immune checkpoint inhibitor treatment. Ann Rheum Dis 2017;76(10):1747-50.
- Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer – clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2017;77(3):393-8.
- Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients with immune checkpoint inhibitors. Autoimmun Rev 2018;17(3):284-9.
- Tocut M, Brenner R, Znadman-Goddard. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018;17(6):610-6.
- Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 2018;67(2):175-182.
Details
Primary Language
Turkish
Subjects
-
Journal Section
Other
Authors
Ayten Yazıcı
*
0000-0003-2167-4509
Türkiye
Publication Date
October 25, 2019
Submission Date
October 19, 2018
Acceptance Date
August 15, 2019
Published in Issue
Year 1970